REDWOOD CITY, Calif., Oct. 29, 2025 /PRNewswire/ -- Codexis, Inc. (CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko Avecia, Inc.

Traditional solid-phase oligonucleotide synthesis is hitting its limits as demand for RNA therapeutics surges. Enzyme-enabled RNA synthesis offers a scalable, sustainable alternative — and leading ...

Most of today's biological and biomedical laboratories simply could not function without ready access to user-specified oligonucleotides. Many researchers rely on core services or external vendors for ...

RNA-based medicines are transforming the way we treat disease—offering targeted, precision therapies for conditions ranging from rare genetic disorders to widespread chronic illnesses like diabetes, ...

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Market Industry Trends and Global Forecasts to 2035: By Application Area, Type of Product Synthesized, Type of Oligonucleotide ...

Utilizing Vapourtec’s R-Series flow chemistry system to undertake their research, the Novo Nordisk team have made the data available in an application note that will be of interest to all chemists ...

Scientists at Novo Nordisk in Denmark have applied flow chemistry to enhance the cleavage of oligonucleotides. Utilizing Vapourtec's R-Series flow chemistry system to undertake their research, the ...